PSC : Randomized Experiments
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Data Collection: Randomized Experiments
9/2/15 STAT 250 Dr. Kari Lock Morgan Knee Surgery for Arthritis Researchers conducted a study on the effectiveness of a knee surgery to cure arthritis. Collecting Data: It was randomly determined whether people got Randomized Experiments the knee surgery. Everyone who underwent the surgery reported feeling less pain. SECTION 1.3 Is this evidence that the surgery causes a • Control/comparison group decrease in pain? • Clinical trials • Placebo Effect (a) Yes • Blinding • Crossover studies / Matched pairs (b) No Statistics: Unlocking the Power of Data Lock5 Statistics: Unlocking the Power of Data Lock5 Control Group Clinical Trials Clinical trials are randomized experiments When determining whether a treatment is dealing with medicine or medical interventions, effective, it is important to have a comparison conducted on human subjects group, known as the control group Clinical trials require additional aspects, beyond just randomization to treatment groups: All randomized experiments need a control or ¡ Placebo comparison group (could be two different ¡ Double-blind treatments) Statistics: Unlocking the Power of Data Lock5 Statistics: Unlocking the Power of Data Lock5 Placebo Effect Study on Placebos Often, people will experience the effect they think they should be experiencing, even if they aren’t actually Blue pills are better than yellow pills receiving the treatment. This is known as the placebo effect. Red pills are better than blue pills Example: Eurotrip 2 pills are better than 1 pill One study estimated that 75% of the -
Efficiency of Average Treatment Effect Estimation When the True
econometrics Article Efficiency of Average Treatment Effect Estimation When the True Propensity Is Parametric Kyoo il Kim Department of Economics, Michigan State University, 486 W. Circle Dr., East Lansing, MI 48824, USA; [email protected]; Tel.: +1-517-353-9008 Received: 8 March 2019; Accepted: 28 May 2019; Published: 31 May 2019 Abstract: It is well known that efficient estimation of average treatment effects can be obtained by the method of inverse propensity score weighting, using the estimated propensity score, even when the true one is known. When the true propensity score is unknown but parametric, it is conjectured from the literature that we still need nonparametric propensity score estimation to achieve the efficiency. We formalize this argument and further identify the source of the efficiency loss arising from parametric estimation of the propensity score. We also provide an intuition of why this overfitting is necessary. Our finding suggests that, even when we know that the true propensity score belongs to a parametric class, we still need to estimate the propensity score by a nonparametric method in applications. Keywords: average treatment effect; efficiency bound; propensity score; sieve MLE JEL Classification: C14; C18; C21 1. Introduction Estimating treatment effects of a binary treatment or a policy has been one of the most important topics in evaluation studies. In estimating treatment effects, a subject’s selection into a treatment may contaminate the estimate, and two approaches are popularly used in the literature to remove the bias due to this sample selection. One is regression-based control function method (see, e.g., Rubin(1973) ; Hahn(1998); and Imbens(2004)) and the other is matching method (see, e.g., Rubin and Thomas(1996); Heckman et al.(1998); and Abadie and Imbens(2002, 2006)). -
Chapter 4: Fisher's Exact Test in Completely Randomized Experiments
1 Chapter 4: Fisher’s Exact Test in Completely Randomized Experiments Fisher (1925, 1926) was concerned with testing hypotheses regarding the effect of treat- ments. Specifically, he focused on testing sharp null hypotheses, that is, null hypotheses under which all potential outcomes are known exactly. Under such null hypotheses all un- known quantities in Table 4 in Chapter 1 are known–there are no missing data anymore. As we shall see, this implies that we can figure out the distribution of any statistic generated by the randomization. Fisher’s great insight concerns the value of the physical randomization of the treatments for inference. Fisher’s classic example is that of the tea-drinking lady: “A lady declares that by tasting a cup of tea made with milk she can discriminate whether the milk or the tea infusion was first added to the cup. ... Our experi- ment consists in mixing eight cups of tea, four in one way and four in the other, and presenting them to the subject in random order. ... Her task is to divide the cups into two sets of 4, agreeing, if possible, with the treatments received. ... The element in the experimental procedure which contains the essential safeguard is that the two modifications of the test beverage are to be prepared “in random order.” This is in fact the only point in the experimental procedure in which the laws of chance, which are to be in exclusive control of our frequency distribution, have been explicitly introduced. ... it may be said that the simple precaution of randomisation will suffice to guarantee the validity of the test of significance, by which the result of the experiment is to be judged.” The approach is clear: an experiment is designed to evaluate the lady’s claim to be able to discriminate wether the milk or tea was first poured into the cup. -
The Theory of the Design of Experiments
The Theory of the Design of Experiments D.R. COX Honorary Fellow Nuffield College Oxford, UK AND N. REID Professor of Statistics University of Toronto, Canada CHAPMAN & HALL/CRC Boca Raton London New York Washington, D.C. C195X/disclaimer Page 1 Friday, April 28, 2000 10:59 AM Library of Congress Cataloging-in-Publication Data Cox, D. R. (David Roxbee) The theory of the design of experiments / D. R. Cox, N. Reid. p. cm. — (Monographs on statistics and applied probability ; 86) Includes bibliographical references and index. ISBN 1-58488-195-X (alk. paper) 1. Experimental design. I. Reid, N. II.Title. III. Series. QA279 .C73 2000 001.4 '34 —dc21 00-029529 CIP This book contains information obtained from authentic and highly regarded sources. Reprinted material is quoted with permission, and sources are indicated. A wide variety of references are listed. Reasonable efforts have been made to publish reliable data and information, but the author and the publisher cannot assume responsibility for the validity of all materials or for the consequences of their use. Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage or retrieval system, without prior permission in writing from the publisher. The consent of CRC Press LLC does not extend to copying for general distribution, for promotion, for creating new works, or for resale. Specific permission must be obtained in writing from CRC Press LLC for such copying. Direct all inquiries to CRC Press LLC, 2000 N.W. -
Week 10: Causality with Measured Confounding
Week 10: Causality with Measured Confounding Brandon Stewart1 Princeton November 28 and 30, 2016 1These slides are heavily influenced by Matt Blackwell, Jens Hainmueller, Erin Hartman, Kosuke Imai and Gary King. Stewart (Princeton) Week 10: Measured Confounding November 28 and 30, 2016 1 / 176 Where We've Been and Where We're Going... Last Week I regression diagnostics This Week I Monday: F experimental Ideal F identification with measured confounding I Wednesday: F regression estimation Next Week I identification with unmeasured confounding I instrumental variables Long Run I causality with measured confounding ! unmeasured confounding ! repeated data Questions? Stewart (Princeton) Week 10: Measured Confounding November 28 and 30, 2016 2 / 176 1 The Experimental Ideal 2 Assumption of No Unmeasured Confounding 3 Fun With Censorship 4 Regression Estimators 5 Agnostic Regression 6 Regression and Causality 7 Regression Under Heterogeneous Effects 8 Fun with Visualization, Replication and the NYT 9 Appendix Subclassification Identification under Random Assignment Estimation Under Random Assignment Blocking Stewart (Princeton) Week 10: Measured Confounding November 28 and 30, 2016 3 / 176 Lancet 2001: negative correlation between coronary heart disease mortality and level of vitamin C in bloodstream (controlling for age, gender, blood pressure, diabetes, and smoking) Stewart (Princeton) Week 10: Measured Confounding November 28 and 30, 2016 4 / 176 Lancet 2002: no effect of vitamin C on mortality in controlled placebo trial (controlling for nothing) Stewart (Princeton) Week 10: Measured Confounding November 28 and 30, 2016 4 / 176 Lancet 2003: comparing among individuals with the same age, gender, blood pressure, diabetes, and smoking, those with higher vitamin C levels have lower levels of obesity, lower levels of alcohol consumption, are less likely to grow up in working class, etc. -
STATS 361: Causal Inference
STATS 361: Causal Inference Stefan Wager Stanford University Spring 2020 Contents 1 Randomized Controlled Trials 2 2 Unconfoundedness and the Propensity Score 9 3 Efficient Treatment Effect Estimation via Augmented IPW 18 4 Estimating Treatment Heterogeneity 27 5 Regression Discontinuity Designs 35 6 Finite Sample Inference in RDDs 43 7 Balancing Estimators 52 8 Methods for Panel Data 61 9 Instrumental Variables Regression 68 10 Local Average Treatment Effects 74 11 Policy Learning 83 12 Evaluating Dynamic Policies 91 13 Structural Equation Modeling 99 14 Adaptive Experiments 107 1 Lecture 1 Randomized Controlled Trials Randomized controlled trials (RCTs) form the foundation of statistical causal inference. When available, evidence drawn from RCTs is often considered gold statistical evidence; and even when RCTs cannot be run for ethical or practical reasons, the quality of observational studies is often assessed in terms of how well the observational study approximates an RCT. Today's lecture is about estimation of average treatment effects in RCTs in terms of the potential outcomes model, and discusses the role of regression adjustments for causal effect estimation. The average treatment effect is iden- tified entirely via randomization (or, by design of the experiment). Regression adjustments may be used to decrease variance, but regression modeling plays no role in defining the average treatment effect. The average treatment effect We define the causal effect of a treatment via potential outcomes. For a binary treatment w 2 f0; 1g, we define potential outcomes Yi(1) and Yi(0) corresponding to the outcome the i-th subject would have experienced had they respectively received the treatment or not. -
Designing Experiments
Designing experiments Outline for today • What is an experimental study • Why do experiments • Clinical trials • How to minimize bias in experiments • How to minimize effects of sampling error in experiments • Experiments with more than one factor • What if you can’t do experiments • Planning your sample size to maximize precision and power What is an experimental study • In an experimental study the researcher assigns treatments to units or subjects so that differences in response can be compared. o Clinical trials, reciprocal transplant experiments, factorial experiments on competition and predation, etc. are examples of experimental studies. • In an observational study, nature does the assigning of treatments to subjects. The researcher has no influence over which subjects receive which treatment. Common garden “experiments”, QTL “experiments”, etc, are examples of observational studies (no matter how complex the apparatus needed to measure response). What is an experimental study • In an experimental study, there must be at least two treatments • The experimenter (rather than nature) must assign treatments to units or subjects. • The crucial advantage of experiments derives from the random assignment of treatments to units. • Random assignment, or randomization, minimizes the influence of confounding variables, allowing the experimenter to isolate the effects of the treatment variable. Why do experiments • By itself an observational study cannot distinguish between two reasons behind an association between an explanatory variable and a response variable. • For example, survival of climbers to Mount Everest is higher for individuals taking supplemental oxygen than those not taking supplemental oxygen. • One possibility is that supplemental oxygen (explanatory variable) really does cause higher survival (response variable). -
Randomized Experimentsexperiments Randomized Trials
Impact Evaluation RandomizedRandomized ExperimentsExperiments Randomized Trials How do researchers learn about counterfactual states of the world in practice? In many fields, and especially in medical research, evidence about counterfactuals is generated by randomized trials. In principle, randomized trials ensure that outcomes in the control group really do capture the counterfactual for a treatment group. 2 Randomization To answer causal questions, statisticians recommend a formal two-stage statistical model. In the first stage, a random sample of participants is selected from a defined population. In the second stage, this sample of participants is randomly assigned to treatment and comparison (control) conditions. 3 Population Randomization Sample Randomization Treatment Group Control Group 4 External & Internal Validity The purpose of the first-stage is to ensure that the results in the sample will represent the results in the population within a defined level of sampling error (external validity). The purpose of the second-stage is to ensure that the observed effect on the dependent variable is due to some aspect of the treatment rather than other confounding factors (internal validity). 5 Population Non-target group Target group Randomization Treatment group Comparison group 6 Two-Stage Randomized Trials In large samples, two-stage randomized trials ensure that: [Y1 | D =1]= [Y1 | D = 0] and [Y0 | D =1]= [Y0 | D = 0] • Thus, the estimator ˆ ˆ ˆ δ = [Y1 | D =1]-[Y0 | D = 0] • Consistently estimates ATE 7 One-Stage Randomized Trials Instead, if randomization takes place on a selected subpopulation –e.g., list of volunteers-, it only ensures: [Y0 | D =1] = [Y0 | D = 0] • And hence, the estimator ˆ ˆ ˆ δ = [Y1 | D =1]-[Y0 | D = 0] • Only estimates TOT Consistently 8 Randomized Trials Furthermore, even in idealized randomized designs, 1. -
Efficient Estimation of Average Treatment Effects Using the Estimated Propensity Score
Econometrica, Vol. 71, No. 4 (July, 2003), 1161-1189 EFFICIENT ESTIMATION OF AVERAGE TREATMENT EFFECTS USING THE ESTIMATED PROPENSITY SCORE BY KiEisuKEHIRANO, GUIDO W. IMBENS,AND GEERT RIDDER' We are interestedin estimatingthe averageeffect of a binarytreatment on a scalar outcome.If assignmentto the treatmentis exogenousor unconfounded,that is, indepen- dent of the potentialoutcomes given covariates,biases associatedwith simple treatment- controlaverage comparisons can be removedby adjustingfor differencesin the covariates. Rosenbaumand Rubin (1983) show that adjustingsolely for differencesbetween treated and controlunits in the propensityscore removesall biases associatedwith differencesin covariates.Although adjusting for differencesin the propensityscore removesall the bias, this can come at the expenseof efficiency,as shownby Hahn (1998), Heckman,Ichimura, and Todd (1998), and Robins,Mark, and Newey (1992). We show that weightingby the inverseof a nonparametricestimate of the propensityscore, rather than the truepropensity score, leads to an efficientestimate of the averagetreatment effect. We provideintuition for this resultby showingthat this estimatorcan be interpretedas an empiricallikelihood estimatorthat efficientlyincorporates the informationabout the propensityscore. KEYWORDS: Propensity score, treatment effects, semiparametricefficiency, sieve estimator. 1. INTRODUCTION ESTIMATINGTHE AVERAGEEFFECT of a binary treatment or policy on a scalar outcome is a basic goal of manyempirical studies in economics.If assignmentto the -
Nber Working Paper Series Regression Discontinuity
NBER WORKING PAPER SERIES REGRESSION DISCONTINUITY DESIGNS IN ECONOMICS David S. Lee Thomas Lemieux Working Paper 14723 http://www.nber.org/papers/w14723 NATIONAL BUREAU OF ECONOMIC RESEARCH 1050 Massachusetts Avenue Cambridge, MA 02138 February 2009 We thank David Autor, David Card, John DiNardo, Guido Imbens, and Justin McCrary for suggestions for this article, as well as for numerous illuminating discussions on the various topics we cover in this review. We also thank two anonymous referees for their helpful suggestions and comments, and Mike Geruso, Andrew Marder, and Zhuan Pei for their careful reading of earlier drafts. Diane Alexander, Emily Buchsbaum, Elizabeth Debraggio, Enkeleda Gjeci, Ashley Hodgson, Yan Lau, Pauline Leung, and Xiaotong Niu provided excellent research assistance. The views expressed herein are those of the author(s) and do not necessarily reflect the views of the National Bureau of Economic Research. © 2009 by David S. Lee and Thomas Lemieux. All rights reserved. Short sections of text, not to exceed two paragraphs, may be quoted without explicit permission provided that full credit, including © notice, is given to the source. Regression Discontinuity Designs in Economics David S. Lee and Thomas Lemieux NBER Working Paper No. 14723 February 2009, Revised October 2009 JEL No. C1,H0,I0,J0 ABSTRACT This paper provides an introduction and "user guide" to Regression Discontinuity (RD) designs for empirical researchers. It presents the basic theory behind the research design, details when RD is likely to be valid or invalid given economic incentives, explains why it is considered a "quasi-experimental" design, and summarizes different ways (with their advantages and disadvantages) of estimating RD designs and the limitations of interpreting these estimates. -
Targeted Estimation and Inference for the Sample Average Treatment Effect
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Collection Of Biostatistics Research Archive University of California, Berkeley U.C. Berkeley Division of Biostatistics Working Paper Series Year 2015 Paper 334 Targeted Estimation and Inference for the Sample Average Treatment Effect Laura B. Balzer∗ Maya L. Peterseny Mark J. van der Laanz ∗Division of Biostatistics, University of California, Berkeley - the SEARCH Consortium, lb- [email protected] yDivision of Biostatistics, University of California, Berkeley - the SEARCH Consortium, may- [email protected] zDivision of Biostatistics, University of California, Berkeley - the SEARCH Consortium, [email protected] This working paper is hosted by The Berkeley Electronic Press (bepress) and may not be commer- cially reproduced without the permission of the copyright holder. http://biostats.bepress.com/ucbbiostat/paper334 Copyright c 2015 by the authors. Targeted Estimation and Inference for the Sample Average Treatment Effect Laura B. Balzer, Maya L. Petersen, and Mark J. van der Laan Abstract While the population average treatment effect has been the subject of extensive methods and applied research, less consideration has been given to the sample average treatment effect: the mean difference in the counterfactual outcomes for the study units. The sample parameter is easily interpretable and is arguably the most relevant when the study units are not representative of a greater population or when the exposure’s impact is heterogeneous. Formally, the sample effect is not identifiable from the observed data distribution. Nonetheless, targeted maxi- mum likelihood estimation (TMLE) can provide an asymptotically unbiased and efficient estimate of both the population and sample parameters. -
Average Treatment Effects in the Presence of Unknown
Average treatment effects in the presence of unknown interference Fredrik Sävje∗ Peter M. Aronowy Michael G. Hudgensz October 25, 2019 Abstract We investigate large-sample properties of treatment effect estimators under unknown interference in randomized experiments. The inferential target is a generalization of the average treatment effect estimand that marginalizes over potential spillover ef- fects. We show that estimators commonly used to estimate treatment effects under no interference are consistent for the generalized estimand for several common exper- imental designs under limited but otherwise arbitrary and unknown interference. The rates of convergence depend on the rate at which the amount of interference grows and the degree to which it aligns with dependencies in treatment assignment. Importantly for practitioners, the results imply that if one erroneously assumes that units do not interfere in a setting with limited, or even moderate, interference, standard estima- tors are nevertheless likely to be close to an average treatment effect if the sample is sufficiently large. Conventional confidence statements may, however, not be accurate. arXiv:1711.06399v4 [math.ST] 23 Oct 2019 We thank Alexander D’Amour, Matthew Blackwell, David Choi, Forrest Crawford, Peng Ding, Naoki Egami, Avi Feller, Owen Francis, Elizabeth Halloran, Lihua Lei, Cyrus Samii, Jasjeet Sekhon and Daniel Spielman for helpful suggestions and discussions. A previous version of this article was circulated under the title “A folk theorem on interference in experiments.” ∗Departments of Political Science and Statistics & Data Science, Yale University. yDepartments of Political Science, Biostatistics and Statistics & Data Science, Yale University. zDepartment of Biostatistics, University of North Carolina, Chapel Hill. 1 1 Introduction Investigators of causality routinely assume that subjects under study do not interfere with each other.